| scholarly article | Q13442814 |
| P356 | DOI | 10.1176/AJP.130.1.82 |
| P698 | PubMed publication ID | 4264755 |
| P2093 | author name string | Klawans HL Jr | |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| dyskinesia | Q629444 | ||
| P304 | page(s) | 82-86 | |
| P577 | publication date | 1973-01-01 | |
| P1433 | published in | American Journal of Psychiatry | Q1935368 |
| P1476 | title | The pharmacology of tardive dyskinesias | |
| P478 | volume | 130 |
| Q64865710 | Q64865710 |
| Q37063790 | 2-Dimethylaminoethanol (Deanol) in Huntington's chorea |
| Q28324194 | A Comparison of Piribedil, Procyclidine and Placebo in the Control of Phenothiazine-induced Parkinsonism |
| Q38062143 | A case study: schizophrenia and tactile hallucinations, treated with electroconvulsive therapy |
| Q71516528 | A comparison of striatal and mesolimbic dopamine function in the rat during 6-month trifluoperazine administration |
| Q41062875 | A neural systems theory of schizophrenia and tardive dyskinesia |
| Q66704525 | Actual or standard bicarbonate? |
| Q39223366 | Acute and chronic haloperidol treatment: Comparison of effects on nigral dopaminergic cell activity |
| Q42670109 | Acute buspirone abolishes the expression of behavioral dopaminergic supersensitivity in mice. |
| Q48563316 | Acute reserpine administration elicits long-term spontaneous oral dyskinesia |
| Q67440465 | Alteration in the action of cholinergic and anti cholinergic drugs after chronic haloperidol: Indirect evidence for cholinergic hyposensitivity |
| Q71539716 | Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion |
| Q72579687 | Altered spontaneous behavior and sensitivity to apomorphine in rats following pretreatment with S(+)-aporphines or fluphenazine |
| Q43436298 | An evaluation of papaverine in tardive dyskinesia |
| Q72534180 | Antiparkinsonian Drugs and Depot Neuroleptics |
| Q47647383 | Antipsychotic agents: a clinical update |
| Q45207542 | Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients |
| Q48667918 | Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis |
| Q41414498 | Attenuation of stereotyped behaviour by sex steroids |
| Q53971010 | Behavioural subsensitivity induced by long-term administration of a low dose of haloperidol to rats. |
| Q38366717 | Biochemical and behavioural properties of clozapine |
| Q52037873 | Biological determinants and risk factors for tardive dyskinesia in schizophrenia. |
| Q40097167 | CNS Dopamine Receptors: Effect of Prolyl-Leucyl-Glycinamide and Solubilization |
| Q72727910 | CSF Monoamine Metabolism in Patients with Tardive Dyskinesia: Effect of Oxypertine and Hydroxyzine Pamoate |
| Q40113701 | Central nervous system receptors in neuropsychiatric disorders |
| Q68691513 | Cholinergic suppression of tardive dyskinesia |
| Q28325354 | Choreoathetosis during Phenytoin Treatment |
| Q43810039 | Chronic ascorbate potentiates the effects of chronic haloperidol on behavioral supersensitivity but not D2 dopamine receptor binding |
| Q48846886 | Chronic elevation of brain GABA by ?-vinyl GABA treatment does not alter the sensitivity of GABAergic or dopaminergic receptors in rat CNS |
| Q49019987 | Chronic haloperidol treatment increased calcium-dependent phosphorylation in rat striatum |
| Q48910243 | Chronic lithium administration has no effect on haloperidol-induced supersensitivity of pre- and postsynaptic dopamine receptors in rat brain |
| Q70802980 | Chronic neuroleptic treatment specifically alters the number of dopamine receptors in rat brain |
| Q38518733 | Chronic neuroleptics alter the effects of the D1 agonist SK&F 38393 and the D2 agonist LY171555 on oral movements in rats |
| Q41534913 | Chronic treatment with 1-dopa plus carbidopa in hemitransected rats: preferential effects at intact dopamine synapses leading to behavioural signs of dopamine receptor supersensitivity |
| Q72524753 | Chronic treatments with zotepine, thioridazine, and haloperidol affect apomorphine-elicited stereotypic behavior and striatal 3H-spiroperidol binding sites in the rat |
| Q45403538 | Clinical Variants of Tardive Dyskinesia in Japan |
| Q66944061 | Clinical and experimental studies of phenytoin-induced hyperkinesias |
| Q41133694 | Clinical and instrumental assessment of neuroleptic-induced parkinsonism in patients with tardive dyskinesia |
| Q48511485 | Clinical features, etiology and treatment of facial dyskinesias in the elderly |
| Q48389855 | Clozapine's functional mesolimbic selectivity is not duplicated by the addition of anticholinergic action to haloperidol: a brain stimulation study in the rat. |
| Q37587974 | Conformation of dopamine at the dopamine receptor |
| Q49122460 | Cortical slow potential shifts in tardive dyskinesia |
| Q48155674 | Deanol acetamidobenzoate inhibits the blood-brain barrier transport of choline |
| Q67496146 | Deanol in tardive dyskinesia: a double-blind study (author's transl) |
| Q67263111 | Deanol in tardive dyskinesia: a preliminary report |
| Q28260250 | Detection of dopaminergic supersensitivity induced by neuroleptic drugs in mice |
| Q44175178 | Development of supersensitivity of apomorphine-induced increases in acetylcholine levels and stereotypy after chronic fluphenazine treatment |
| Q35221971 | Diagnostic problems in Huntington's chorea and tardive dyskinesia |
| Q69233044 | Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride |
| Q48159730 | Differential distribution of biogenic amines in the hypoglossal nucleus of the rat. |
| Q41749031 | Dopamine agonists reverse the elevated 3H-neuroleptic binding in neuroleptic-pretreated rats |
| Q41040188 | Dopamine binding following prolonged haloperidol pretreatment |
| Q69581947 | Dopamine receptor site sensitivity in hyperthyroid guinea pigs: A possible model of hyperthyroid chorea |
| Q40243147 | Dopamine receptors in the central nervous system. |
| Q39643228 | Dopamine-containing neurons in the mammalian central nervous system: electrophysiology and pharmacology |
| Q69330809 | Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia |
| Q52511358 | Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats: support for a model of tardive dyskinesia. |
| Q39128574 | Drug Therapy of Tardive Dyskinesia |
| Q45303634 | Drug-Induced Tardive Dyskinesia |
| Q74013515 | Drug-induced movement disorders |
| Q41393959 | Dyskinesias Evoked in Monkeys by Weekly Administration of Haloperidol |
| Q48772369 | Dyskinesias in the geriatric population |
| Q48400646 | Ebselen attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum |
| Q37101720 | Effect of cholinergic and anticholinergic agents on tardive dyskinesia |
| Q74164915 | Effects of age on a new animal model of tardive dyskinesia |
| Q73346170 | Effects of buspirone on an animal model of tardive dyskinesia |
| Q42661312 | Effects of buspirone on dopaminergic supersensitivity |
| Q48560854 | Effects of discontinuous drug administration on the development of dopamine receptor supersensitivity during chronic trifluoperazine or cis-flupenthixol administration to rats |
| Q72459758 | Effects of dopaminergic and cholinergic drugs. naloxone and l-prolyl-leucyl-glycinamide on LSD-induced catalepsy |
| Q28319229 | Effects of estrogens on the characteristics of [3H]spiroperidol and [3H]RU24213 binding in rat anterior pituitary gland and brain |
| Q48500113 | Effects of haloperidol and GM1 ganglioside treatment on striatal D2 receptor binding and dopamine turnover |
| Q74014176 | Effects of monosialoganglioside on a new model of tardive dyskinesia |
| Q69951804 | Effects of tiapride in tardive dyskinesia |
| Q44472615 | Effects of valproic acid on an animal model of tardive dyskinesia. |
| Q28374552 | Enhanced striatal dopamine D(2) receptor-induced [35S]GTPgammaS binding after haloperidol treatment |
| Q55954267 | Excitation-mediating and inhibition-mediating dopamine-receptors: A new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data |
| Q28336747 | Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients |
| Q52290901 | Facilitation of active avoidance responding following chronic haloperidol treatment in rats. |
| Q46801419 | Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients |
| Q54130707 | GABA agonists in cebus monkeys with neuroleptic-induced persistent dyskinesias. |
| Q39080881 | Importance of O-methylation in dopamine-induced motor and behavioral phenomena |
| Q72013300 | Increased body movements during sleep in Gilles de la Tourette syndrome |
| Q71543789 | Increased mesolimbic dopamine binding following chronic haloperidol treatment |
| Q48561343 | Increased or decreased locomotor response in rats following repeated administration of apomorphine depends on dosage interval |
| Q39701911 | Ineffectiveness of deanol in tardive dyskinesia: A placebo controlled study |
| Q46866478 | Influence of female sex hormones on neuroleptic-induced behavioral supersensitivity |
| Q45038523 | Intranigral infusion of enkephalins elicits dyskinetic biting in rats |
| Q35028210 | L-3,4-dihydroxyphenylalanine-induced hypersensitivity simulating features of denervation |
| Q41966077 | L-DOPA reversal of hyperdopaminergic behaviour |
| Q48251131 | L-dopa causes an acute, partial and reversible reversal of denervation-induced supersensitivity of striatal dopaminergic receptors |
| Q28337977 | Letter: Potentiation of tardive dyskinesia: possible drug interaction |
| Q72540456 | Levodopa and receptor sensitivity modification in tardive dyskinesia |
| Q70481855 | Lithium does not interact with haloperidol in the dopaminergic pathways of the rat brain |
| Q38749646 | Locus coeruleus-pineal melatonin interactions and the pathogenesis of the "on-off" phenomenon associated with mood changes and sensory symptoms in Parkinson's disease |
| Q44597801 | Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors |
| Q40293027 | Long-term regulation of muscarinic acetylcholine receptors on cultured nerve cells |
| Q40298512 | Low dose fluphenazine decanoate in maintenance treatment of schizophrenia |
| Q40334101 | Management of tardive dyskinesia: current update |
| Q38285281 | Medical Treatment of Mental Illness |
| Q42271859 | Methylphenidate, neuroleptics and dyskinesia-dystonia |
| Q39299829 | Metoclopramide and Haloperidol in Tardive Dyskinesia |
| Q34551409 | Metoclopramide and tardive dyskinesia in the elderly |
| Q116369865 | Monoamine oxidase inhibitors antagonize the acceleration of brain dopamine synthesis induced by neuroleptic drugs in vivo: Implications for the treatment of tardive dyskinesia |
| Q40326024 | Monoamine oxidase inhibitors antagonize the acceleration of brain dopamine synthesis induced by neuroleptic drugs in vivo: implications for the treatment of Tardive dyskinesia |
| Q41216081 | Mood-dependent fluctuations in the severity of tardive dyskinesia and psoriasis vulgaris in a patient with schizoaffective disorder: possible role of melatonin |
| Q40089993 | Neurotransmitter deficits in Alzheimer's disease: criteria for significance |
| Q39510599 | New Approaches in the Management of Hyperkinetic Movement Disorders |
| Q39298593 | Normal prolactin responses in tardive dyskinesia |
| Q45044695 | Nucleotide requirement of dopamine sensitive adenylate cyclase in synaptosomal membranes from the striatum of rat brain |
| Q72427279 | Oral dyskinesia in brain-damaged rats withdrawn from a neuroleptic: Implication for models of tardive dyskinesia |
| Q34050289 | Orofacial dyskinesia. Clinical features, mechanisms and drug therapy |
| Q39241892 | Palatal myoclonus and denervation supersensitivity in the central nervous system |
| Q48760491 | Permanent haloperidol-induced dopamine receptor up-regulation in the ovariectomized rat |
| Q37791156 | Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry |
| Q41321291 | Pharmacological characterization of tardive dyskinesia |
| Q41258822 | Pharmacological options for the management of dyskinesias |
| Q39773343 | Pharmacology and Neurochemistry of Apomorphine |
| Q28332127 | Phenytoin and Choreic Movements |
| Q28332534 | Phenytoin-induced hyperkinesia |
| Q40273062 | Physostigmine, but not neostigmine, inhibits acetylcholine release |
| Q39662616 | Plasmatic renin activity in patients treated with l-dopa and inhibitor of dopa decarboxylase (IDC) |
| Q66704526 | Platelet monoamine oxidase and plasma dopamine beta-hydroxylase in tardive dyskinesia |
| Q71960292 | Polymorphic Drug Metabolism in Schizophrenic Patients With Tardive Dyskinesia |
| Q44926991 | Preliminary Communication Absence of cardiac deceleration in a signalled escape paradigm: a psychophysiological deficit in chronic schizophrenia |
| Q48253788 | Presynaptic dopamine receptors. Development of supersensitivity following treatment with fluphenazine decanoate |
| Q52072398 | Prolactin response to sodium valproate in schizophrenics with and without tardive dyskinesia. |
| Q72465316 | Propranolol (inderal) for tardive dyskinesia and extrapyramidal side effects from neuroleptics: Possible involvement of beat - adrenergic mechanisms |
| Q49011393 | Psychosis associated with water intoxication: psychogenic polydipsia or concomitant dopaminergic supersensitivity disorders? |
| Q28332518 | Pyridoxine improves drug-induced parkinsonism and psychosis in a schizophrenic patient |
| Q48190564 | Receptor basis for dopaminergic supersensitivity in Parkinson's disease |
| Q48854637 | Reduction of nigral glutamic acid decarboxylase in rats with neuroleptic-induced oral dyskinesia |
| Q41261698 | Regional homovanillic acid levels and oral movements in rats following chronic haloperidol treatment |
| Q39268634 | Relationship of Mitten Patterns to Neuroleptic Drug Induced Dyskinesias in Psychiatric Patients: Early Investigative Findings |
| Q39300277 | Relationship of the Actions of Neuroleptic Drugs to the Pathophysiology of Tardive Dyskinesia |
| Q37075326 | Relevance of the Habenular Complex to Neuropsychiatry: A Review and Hypothesis |
| Q69915821 | Remoxipride, a selective dopamine D2 receptor antagonist, in tardive dyskinesia |
| Q34269658 | Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia |
| Q41683349 | Reversibility of Tardive Dyskinesia |
| Q48620261 | Risk factors for neuroleptic-induced movement disorders |
| Q72235753 | Schizophrenia |
| Q39310386 | Short and long-term effects of neuroleptics in relation to their cellular mechanism of action |
| Q39222935 | Six month evaluation of thiopropazate hydrochloride in tardive dyskinesia |
| Q35570924 | Stimulants: interaction with clinically relevant drugs |
| Q68409101 | Striatal binding of 11C-NMSP studied with positron emission tomography in patients with persistent tardive dyskinesia: no evidence for altered dopamine D2 receptor binding |
| Q33396727 | Structural and functional brain imaging in schizophrenia |
| Q52757958 | Sub-syndromes of tardive dyskinesia. |
| Q33589103 | Sulpiride in tardive dyskinesia |
| Q48254787 | Supersensitivity to apomorphine and stress two years after chronic methadone treatment |
| Q44252546 | Supersensitivity to d-amphetamine- and apomorphine-induced stereotyped behavior induced by chronic d-amphetamine administration |
| Q52714036 | Susceptibility to amphetamine-elicited dyskinesias following chronic methadone treatment in monkeys. |
| Q39951009 | Tardive Dyskinesia: An Evaluation of the Etiologic Association with Neuroleptic Therapy |
| Q46327667 | Tardive dyskinesia and informed consent |
| Q41175822 | Tardive dyskinesia associated with depression in a bipolar patient: possible role of melatonin |
| Q67248909 | Tardive dyskinesia associated with metoclopramide |
| Q38018562 | Tardive dyskinesia in bipolar disorders: possible role of pineal melatonin |
| Q71314972 | Tardive dyskinesia in depressed patients: successful therapy with antidepressants and lithium |
| Q43938523 | Tardive dyskinesia model in the common marmoset |
| Q72437711 | Tardive dyskinesia on Hungarian psychiatric wards |
| Q51824379 | Tardive dyskinesia uncovered after ingestion of Sominex, an over-the-counter drug. |
| Q43449207 | Tardive dyskinesia with inflated neurons of the cerebellar dentate nucleus. Case reports and morphometric study |
| Q40227017 | Tardive dyskinesia: A clinical test of the supersensitivity hypothesis |
| Q39615570 | Tardive dyskinesia: Age and sex differences in hospitalized schizophrenics |
| Q72551912 | Tardive dyskinesia: a 3-year follow-up study |
| Q67587116 | The demonstration of a change in responsiveness of mice to physostigmine and atropine after withdrawal from long-term haloperidol pretreatment |
| Q72961714 | The effect of hemodialysis on tardive dyskinesia |
| Q53996411 | The effect of lithium on an animal model of tardive dyskinesia |
| Q67429369 | The effect of long-term penfluridol treatment on the sensitivity of the dopamine receptors in the nucleus accumbens and in the corpus striatum |
| Q71101547 | The effect of methylphenidate on tardive dyskinesia |
| Q48612111 | The effect of the potential antipsychotic ORG 5222 on local cerebral glucose utilization in freely moving rats |
| Q39128600 | The effects of antipsychotics on the turnover rate of GABA and acetylcholine in rat brain nuclei |
| Q40082232 | The pathophysiology of extrapyramidal side-effects of neuroleptic drugs |
| Q40082826 | The physiology and pharmacology of mammalian basal ganglia |
| Q40701172 | The relationship between diabetes mellitus and Parkinson's disease |
| Q41178359 | The relationship of negative schizophrenia to parkinsonism |
| Q35281449 | The relationship of pineal calcification and melatonin secretion to the pathophysiology of tardive dyskinesia and Tourette's syndrome |
| Q41169733 | The relationship of tardive dyskinesia to positive schizophrenia |
| Q41359440 | The specificity of neuroleptic- and methysergide-induced behavioral hypersensitivity |
| Q45232326 | The treatment of tardive dyskinesia with baclofen |
| Q39217378 | Therapeutic Trials in Tardive Dyskinesia |
| Q70477117 | Treatment schedule as a determinant of the development of tolerance to haloperidol |
| Q50963279 | Urea or creatinine? |
| Q72579647 | Vacuous jaw movements induced by sub-chronic administration of haloperidol: interactions with scopolamine |
| Q28326260 | Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia |
Search more.